Metabolic Syndrome And Cardiovascular Disease

Addressing a topic of utmost importance in the field, this text addresses the epidemiology, diagnosis, assessment, and management of patients with metabolic syndrome-focusing on implications for cardiovascular disease risk. With an abundance of clearly organized tables, flowcharts, and practice guidelines, this blue-ribbon source succinctly analyze

Trends indicate that the metabolic syndrome will become the leading risk factor for heart disease. Now more than ever you need an all-in-one reference that provides the tools and practical advice you need to: Identify at-risk patients Explain individual contributing factors Aid in patient education and motivation Direct comprehensive care and Choose the most appropriate interventions Comprehensively revised to reflect leading-edge research and now organized to facilitate easy access to essential information and clinically-relevant guidance, Metabolic Syndrome and Cardiovascular Disease, 2e offers this and more. Not only will you receive a solid understanding of the pathophysiology underlying the metabolic syndrome and cardiovascular disease but also the rationale for today’s most effective treatments. What’s new? Filled with timely new content, this updated edition covers: New discoveries that have changed our understanding of the pathogenesis and interrelationship of metabolic syndrome, cardiovascular disease (CHD), and type 2 diabetes mellitus (DM) The relevance of mitochondria and telomeres Sleep and its impact on cardiometabolic health The pivotal interplay between insulin and forkhead transcriptionfactors Calorie restriction research Bariatric surgery experiences and outcomes In addition, each chapter includes essential information on comorbidities, interventions, and pharmacotherapeutic options – an exclusive feature found only in the second edition!

The relationship of metabolic diseases to cardiovascular disease (CVD) is reaching epidemic proportions. This relates mostly to the increasing prevalence of obesity, the metabolic syndrome and type 2 diabetes. This book outlines and addresses the metabolic factors and related diseases that contribute to CVD, including brief introductions to metabolic pathways including lipid and lipoprotein metabolism, macronutrient fuel partitioning, insulin action and body weight regulation. Mechanisms that relate to becoming obese, maintenance of the obese state, the dyslipidemias, and glucose intolerance/diabetes are also addressed, and the importance of interventions that reduce metabolic risk factors and CVD are covered.

Metabolic syndrome is a dangerous combination of cardiovascular risk factors that correlate with each other and can increase cardio and cerebrovascular events. The incidence of metabolic syndrome often parallels that of obesity and type 2 diabetes. It is widespread; in the United States, more than 40% of people over the age of 50 have metabolic syndrome. The diagnosis of metabolic syndrome is based on the coexistence of at least three risk factors including waist circumference greater than 102 cm in men or 88 cm in women, systolic blood pressure greater than 130 mmHg and diastolic greater than 85 mmHg, HDL cholesterol less than 40 mg/dl in men or 50 mg/dl in women, triglyceridemia higher than 150 mg/dl and finally fasting glycaemia higher than 110 mg/dl.

Explores the underlying mechanisms of insulin resistance and the metabolic syndrome as they relate to coronary heart disease, heart failure, hypertension, and secondary cardiovascular problems. Combines theory with practice in meaningful applications that detail how to manage your at-risk patients. Provides the help needed to formulate rational therapeutic interventions that will effectively prevent or mitigate the manifestations of the conditions that have emerged as key precursors to cardiovascular disease.

The Metabolic Syndrome is a valuable reference text, covering all aspects of the metabolic syndrome and its constituent diseases including inflammation, oxidation and adipocytokines. This book explains the aetiology, pathogenesis and clinical treatment of all risk factors as well as the relationship with diabetes, non alcoholic fatty liver disease, polycystic ovary syndrome and coronary heart disease. The Metabolic Syndrome has been further improved from the 1st edition that was highly commended in 2006 Annual British Medical Association medical books competition. All chapters from the first edition are fully updated and this new edition contains an increase in international contributions and five new chapters on: Childhood obesity and metabolic syndrome Bariatric surgery for obesity Fitness Brain insulin resistance and appetite The nature of the insulin resistance seen in metabolic syndrome. This brand new edition of The Metabolic Syndrome will be an indispensable resource for all clinical researchers, physicians and scientists requiring detailed up-to-date information on the metabolic syndrome to further their own research or to treat and manage the syndrome and its complications. Specifically, the text will be of particular relevance to those involved and working in the fields of diabetes, endocrinology, obesity, cardiology, vascular disease and hepatology.

Metabolic syndrome is a set of risk factors that includes: abdominal obesity, a decreased ability to process glucose (insulin resistance), dyslipidemia (unhealthy lipid levels), and hypertension. Patients who have this syndrome have been shown to be at an increased risk of developing cardiovascular disease and/or type 2 diabetes. Metabolic syndrome is a common condition that goes by many names (dysmetabolic syndrome, syndrome X, insulin resistance syndrome, obesity syndrome, and Reaven's syndrome). This is the first book to fully explain the relationships between psychiatric illness, Metabolic Syndrome, diet, sleep, exercise, medications, and lifestyle choices. Metabolic Syndrome is a major risk factor in Major Depression, Alzheimer's Disease, Sleep Disorders, Sexual Dysfunction, Fibromyalgia, and several other illnesses of psychiatric significance. Conversely, some psychiatric illnesses tend to predispose patients to Metabolic Syndrome. Of further interest is the fact that some of the medications used in the treatment of psychiatric illnesses have been found to cause or exacerbate Metabolic Syndrome. The author here provides basic information about what genetic predispositions, medical conditions, and lifestyle choices make Metabolic Syndrome more likely to occur. Among the contributing factors that are discussed are genetics, habitual intake of high glycemic index carbohydrates, fructose, saturated fats, trans fatty acids, vitamins, micronutrients, obesity, smoking, and lack of exercise. The author describes the actual mechanisms by which Metabolic Syndrome progresses and causes damage in the body, including the action of insulin and the pathophysiology of insulin resistance. Details are provided on what occurs in the liver, pancreas, muscle, fat cells, and immune system as Metabolic Syndrome progresses. New findings are presented on fat cells, including the fact that they are beginning to be considered as endocrine cells. There is a substantive discussion of leptin, which is one of the important adipocytokines. Also carbohydrate, 'bad fats', inflammation, oxidative damage, over-stimulation of the 'fight or flight' system, and high levels of the stress hormone cortisol can actually cause the manifestations of Metabolic Syndrome. These explanations set the stage for an explanation of the inter-relationships between Metabolic Syndrome, psychiatric illness, dementia and effects of not only diet and life choices, but also the effects of psychiatric medications. Finally, there is an important and unique section on the relationship between Metabolic Syndrome and various psychiatric illnesses, and how they exacerbate each other. The significance of Metabolic Syndrome in Major Depression, Bipolar Affective Disorder, Schizophrenia, fibromyalgia and Polycystic Ovary Disease is vast and it is important to realise the effects of psychiatric medications on Metabolic Syndrome. The author discusses antidepressants, mood stabilizers and the new atypical antipsychotics. There are dramatic differences among medications in the way they affect Metabolic Syndrome and pharmaceutical companies will want to promote patient awareness with this book.